GlassScriptPhysician profile
Ashley Watson
NPI 1427454826
$2,107.88
in general payments reported to CMS, 2019-2025
24 companies · $525 in 2025
The $525 reported for 2025 was more than what 77% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $229 · 2023: $605 · 2024: $580 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.37 |
| Education | $320.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $359.54 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $251.41 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $230.48 | 2021-2025 | Tezspire |
| Genzyme Corporation | $162.62 | 2023-2024 | |
| Harmony Biosciences LLC | $158.40 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $142.01 | 2025 | Dupixent |
| United Therapeutics Corporation | $138.59 | 2022-2025 | Tyvaso |
| Mylan Specialty L.P. | $107.40 | 2023-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $88.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $53.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.10 | 2022-2023 | Ofev |
| Axsome Therapeutics, INC. | $45.95 | 2023 | Sunosi |
| Ucb, INC. | $41.77 | 2022-2023 | Briviact |
| Pfizer INC. | $36.99 | 2023 | |
| Insmed, INC. | $35.04 | 2025 | Brinsupri, Arikayce |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.22 | 2024 | Glassia |
| Sk Life Science, INC. | $25.78 | 2022 | |
| Neurocrine Biosciences, INC. | $25.67 | 2025 | |
| Viatris Specialty LLC | $23.33 | 2025 | Yupelri |
| Baxter Healthcare | $19.02 | 2023 | Hillrom - Life 2000 Ventilation System |
| Eisai INC. | $18.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.02 | 2021 | |
| Pulmonx Corporation | $17.90 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.